From Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy:

Neurocrine Biosciences CEO Kevin Gorman
Neurocrine Biosciences CEO Kevin Gorman

Headshot of Kevin Gorman, courtesy of Neurocrine Biosciences